Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dianhydrogalactitol
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Minakem (formerly Delmar Chemicals)
Deal Size : Undisclosed
Deal Type : Acquisition
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
Details : This combination brings together DelMar's first-in-class, DNA-targeting chemotherapeutic with proven anti-cancer activities with Adgero's photodynamic therapy platform.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 10, 2020
Lead Product(s) : Dianhydrogalactitol
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Minakem (formerly Delmar Chemicals)
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?